Tata Investment Corporation Ltd
₹564.50
+11.60 (2.10%)
Fri, 06 Nov 2026, 09:02 pm
Tata Investment Corporation News
Tata Investment Q2 revenue falls to 1.22B rupees
Tata Investment Corporation reported Q2 revenue of 1.22B rupees, down from 1.54B rupees in the same period a year ago, reflecting a YoY decline.
02 Nov 2026
companies
Tata Investment closes trading window for Q2FY27
Tata Investment Corporation Ltd has closed its trading window from September 24, 2026, until 48 hours after the declaration of its financial results for the quarter and half year ended September 30, 2026.
24 Sept 2026
companies
Tata Investment gets ESG rating of 62
Tata Investment Corporation received an ESG rating of 62 (Strong) from ESG Risk Assessments & Insights Limited based on public data.
07 Jul 2026
companies
Tata Investment declares dividend for FY26
Tata Investment Corporation Ltd approved a dividend of Rs. 3.40 per share for FY26 at its AGM. All four resolutions, including financial statements and director re-appointment, were passed.
01 Jul 2026
companies
Tata Investment closes trading window from June 24
Tata Investment Corporation closed its trading window from June 24, 2026, until 48 hours after Q1FY27 results are declared.
19 Jun 2026
companies
Market Current News
CONTINENTAL CONTROLS LTD.
Continental Controls rights issue oversubscribed
Continental Controls Limited completed its rights issue of 1.96 crore shares at ₹10 each. The issue was oversubscribed 112.75% and shares list on BSE on November 5, 2026.
05 Nov 2026
ipo
Jivial Industries Limited
Jivial Industries changes IPO machinery vendors
Jivial Industries Ltd approved partial vendor changes for three machinery sets in its IPO project. Costs and timelines remain unchanged despite the switch.
05 Nov 2026
ipo
Antala IPO Day 6: Subscribed 6.43x
Antala Industries IPO sees strong QIB demand at 66.72x on final day. Total subscription reaches 6.43x as Retail and NII interest picks up.
05 Nov 2026
ipo
IGL Spirits lists on BSE and NSE post-demerger
IGL Spirits Limited listed on BSE and NSE on November 4, 2026. The demerged entity reported FY26 revenue of ₹2,801 crore and EBITDA of ₹492 crore.
04 Nov 2026
ipo
Ennature Bio Pharma lists on NSE, BSE
Ennature Bio Pharma Limited listed on NSE and BSE on November 4, 2026. The biopharma division reported ₹246 crore revenue in FY26, driven by branded nutraceuticals.
04 Nov 2026
ipo